Shanghai Ultra-T Immune Therapeutics

Shanghai Ultra-T Immune Therapeutics is a wholly-owned subsidiary of Novatim Immune Therapeutics (Zhejiang) Co., Ltd. It was established on November 11, 2018, and is located in Shanghai, China. The company is a biopharmaceutical technology enterprise specializing in the research and clinical application of innovative drugs in the field of tumor immunotherapy. Ultra-T Immune Therapeutics primarily focuses on the research and clinical application of CAR-T cell immunotherapy. With a deep involvement in precision immunotherapy since 2013, the company has established a comprehensive research and production platform covering antibody screening to CAR-T preparation. The company places a significant emphasis on developing highly original therapeutic products. Currently, Ultra-T Immune Therapeutics has obtained multiple patents, including inventions such as a TM4SF1-specific chimeric antigen receptor and its application, a monomeric antibody against BCMA and its application, and a chimeric antigen receptor targeting EpCAM and its application.